Genetic Immunity Inc., is a privately-held, U.S. biopharmaceutical company that has developed a proprietary Langerhans cell targeting delivery system which can induce long-lasting T cell immunity for therapeutic vaccinations against infectious diseases and cancer. Our proprietary system delivers a genetically targeted nanomedicine formulation that can simultaneously express 15 disease-specific antigens. All of our medicines are delivered topically using our CE-marked medical device, DermaPrep™. Today, the National Institutes of Health (NIH) is sponsoring a clinical trial in 72 HIV-positive adolescents. Genetic Immunity plans to start a Phase IIB study on 120 HIV-positive adults and a Phase II study on Hepatitis C/HIV co-infected patients the later part of 2012. For more information on the Company, our products and our trials, please visit us on the web at: www.geneticimmunity.com.